Total Payments
$395,698
2024 Payments
$6,023
Companies
33
Transactions
399
Medicare Patients
3,865
Medicare Billing
$430,308
Payment Breakdown by Category
Other$257,032 (65.0%)
Consulting$77,425 (19.6%)
Travel$49,404 (12.5%)
Food & Beverage$8,837 (2.2%)
Research$3,000 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $249,377 | 79 | 63.0% |
| Consulting Fee | $77,425 | 24 | 19.6% |
| Travel and Lodging | $49,404 | 138 | 12.5% |
| Food and Beverage | $8,837 | 151 | 2.2% |
| Honoraria | $4,155 | 5 | 1.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,500 | 1 | 0.9% |
| Unspecified | $3,000 | 1 | 0.8% |
Payments by Type
General
$392,698
398 transactions
Research
$3,000
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Daiichi Sankyo Inc. | $132,750 | 117 | $0 (2019) |
| Pernix Therapeutics Holdings, Inc. | $92,315 | 110 | $0 (2019) |
| Scilex Pharmaceuticals Inc. | $42,248 | 24 | $0 (2019) |
| Depomed, Inc. | $33,438 | 39 | $0 (2017) |
| Collegium Pharmaceutical, Inc. | $26,099 | 13 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $18,341 | 13 | $0 (2019) |
| Kaleo, Inc. | $6,497 | 6 | $0 (2017) |
| Heron Therapeutics, Inc. | $5,002 | 14 | $0 (2021) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $4,628 | 10 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $4,091 | 5 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,023 | 2 | Collegium Pharmaceutical, Inc. ($5,925) |
| 2023 | $20,415 | 9 | Collegium Pharmaceutical, Inc. ($12,000) |
| 2022 | $178.49 | 2 | GRT US Holding, Inc. ($110.00) |
| 2021 | $5,516 | 8 | GRT US Holding, Inc. ($2,655) |
| 2020 | $3,130 | 4 | PFIZER INC. ($2,970) |
| 2019 | $41,697 | 43 | Daiichi Sankyo Inc. ($11,111) |
| 2018 | $109,550 | 102 | Pernix Therapeutics Holdings, Inc. ($38,553) |
| 2017 | $209,188 | 229 | Daiichi Sankyo Inc. ($84,991) |
All Payment Transactions
399 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/10/2024 | Collegium Pharmaceutical, Inc. | Xtampza (Drug), Belbuca | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,925.00 | General |
| Category: Opioid Analgesic | ||||||
| 04/05/2024 | Curonix LLC | PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A (Device) | Food and Beverage | Cash or cash equivalent | $97.95 | General |
| Category: PAIN MANAGEMENT | ||||||
| 11/04/2023 | SPR Therapeutics, Inc | SPRINT PNS System (Device) | Food and Beverage | Cash or cash equivalent | $66.00 | General |
| Category: Pain management | ||||||
| 10/26/2023 | Boston Scientific Corporation | WaveWriter Alpha Prime 16 (Device) | Food and Beverage | In-kind items and services | $111.24 | General |
| Category: WaveWriter Alpha_NMD | ||||||
| 10/12/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $857.00 | General |
| Category: Gastroenterology | ||||||
| 09/28/2023 | Noven Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 09/07/2023 | Tris Pharma Inc | — | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| 09/07/2023 | Tris Pharma Inc | — | Food and Beverage | In-kind items and services | $75.52 | General |
| 09/07/2023 | Tris Pharma Inc | — | Food and Beverage | In-kind items and services | $55.59 | General |
| 06/08/2023 | Collegium Pharmaceutical, Inc. | Xtampza (Drug), Belbuca, Nucynta | Consulting Fee | Cash or cash equivalent | $12,000.00 | General |
| Category: Opioid Analgesic | ||||||
| 06/08/2023 | Purdue Pharma L.P. | — | — | Cash or cash equivalent | $3,000.00 | Research |
| Study: PMR 3033-11: Study 11 | ||||||
| 05/06/2022 | GRT US Holding, Inc. | Qutenza (Drug) | Food and Beverage | In-kind items and services | $110.00 | General |
| Category: Pain Management | ||||||
| 05/04/2022 | Stimwave Technologies Incorporated | StimQ Receiver Stimulator Kit Channel A US w/Receiver (Device), StimQ Freedom-4A Receiver Kit Channel A US w/ Receiver, StimQ Freedom-8A Receiver Kit Channel A US w/ Receiver | Food and Beverage | Cash or cash equivalent | $68.49 | General |
| Category: Neurostimulation | ||||||
| 11/09/2021 | BOSTON SCIENTIFIC CORPORATION | WAVEWRITER ALPHA (Device) | Food and Beverage | In-kind items and services | $106.47 | General |
| Category: PAIN MANAGEMENT | ||||||
| 09/17/2021 | Heron Therapeutics, Inc. | Zynrelef (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Postoperative Pain | ||||||
| 09/01/2021 | Heron Therapeutics, Inc. | Zynrelef (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Postoperative Pain | ||||||
| 08/11/2021 | GRT US Holding, Inc. | Qutenza (Drug) | Food and Beverage | In-kind items and services | $54.77 | General |
| Category: Pain Management | ||||||
| 05/12/2021 | Baudax Bio Inc. | ANJESO (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Pain Management | ||||||
| 04/16/2021 | GRT US Holding, Inc. | Qutenza (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: Pain Management | ||||||
| 04/13/2021 | GRT US Holding, Inc. | Qutenza (Drug) | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| Category: Pain Management | ||||||
| 01/25/2021 | Baudax Bio Inc. | ANJESO (Drug) | Honoraria | Cash or cash equivalent | $1,105.00 | General |
| Category: Pain Management | ||||||
| 12/18/2020 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| 11/05/2020 | Baudax Bio Inc. | ANJESO (Drug) | Food and Beverage | In-kind items and services | $159.91 | General |
| Category: Pain Management | ||||||
| 07/20/2020 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $314.00 | General |
| 05/04/2020 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,256.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PMR 3033-11: Study 11 | Purdue Pharma L.P. | $3,000 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 1,027 | 1,500 | $1.4M | $128,021 |
| 2022 | 15 | 991 | 1,476 | $1.4M | $121,126 |
| 2021 | 15 | 977 | 1,479 | $1.3M | $104,069 |
| 2020 | 14 | 870 | 1,268 | $1.0M | $77,091 |
Total Patients
3,865
Total Services
5,723
Medicare Billing
$430,308
Procedure Codes
58
All Medicare Procedures & Services
58 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 203 | 398 | $244,770 | $44,914 | 18.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 157 | 157 | $156,529 | $23,422 | 15.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 143 | 256 | $107,520 | $20,216 | 18.8% |
| 62323 | Injection of substance into lower spine canal using imaging guidance | Office | 2023 | 126 | 165 | $429,000 | $14,707 | 3.4% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 64 | 86 | $70,950 | $3,483 | 4.9% |
| 77002 | Fluoroscopic guidance for needle placement | Office | 2023 | 97 | 142 | $58,930 | $3,450 | 5.9% |
| 20552 | Injection of trigger points, 1-2 muscles | Office | 2023 | 94 | 131 | $97,464 | $3,191 | 3.3% |
| 64493 | Injection of lower or sacral spine facet joint using imaging guidance, single level | Office | 2023 | 33 | 39 | $81,900 | $3,186 | 3.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 17 | 20 | $16,900 | $2,060 | 12.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 13 | $22,009 | $2,054 | 9.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 19 | 19 | $16,150 | $1,991 | 12.3% |
| 64483 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | Office | 2023 | 16 | 19 | $31,445 | $1,939 | 6.2% |
| 64494 | Injection of lower or sacral spine facet joint using imaging guidance, second level | Office | 2023 | 32 | 38 | $41,800 | $1,740 | 4.2% |
| 62321 | Injection of substance into middle or upper spine canal using imaging guidance | Office | 2023 | 13 | 17 | $49,113 | $1,670 | 3.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 150 | 308 | $189,420 | $36,631 | 19.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 180 | 330 | $138,600 | $26,228 | 18.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 101 | 101 | $100,697 | $15,780 | 15.7% |
| 62323 | Injection of substance into lower spine canal using imaging guidance | Office | 2022 | 115 | 148 | $384,800 | $13,010 | 3.4% |
| 64493 | Injection of lower or sacral spine facet joint using imaging guidance, single level | Office | 2022 | 40 | 62 | $130,200 | $5,085 | 3.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 46 | 46 | $39,100 | $3,753 | 9.6% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 55 | 74 | $61,050 | $2,975 | 4.9% |
| 64494 | Injection of lower or sacral spine facet joint using imaging guidance, second level | Office | 2022 | 40 | 60 | $66,000 | $2,894 | 4.4% |
| 77002 | Fluoroscopic guidance for needle placement | Office | 2022 | 81 | 110 | $45,650 | $2,687 | 5.9% |
| 20552 | Injection of trigger points, 1-2 muscles | Office | 2022 | 76 | 105 | $78,120 | $2,515 | 3.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 20 | 25 | $20,995 | $2,342 | 11.2% |
About Dr. Christopher Gharibo, M.D
Dr. Christopher Gharibo, M.D is a Anesthesiology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/04/2005. The National Provider Identifier (NPI) number assigned to this provider is 1073500013.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Gharibo, M.D has received a total of $395,698 in payments from pharmaceutical and medical device companies, with $6,023 received in 2024. These payments were reported across 399 transactions from 33 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($249,377).
As a Medicare-enrolled provider, Gharibo has provided services to 3,865 Medicare beneficiaries, totaling 5,723 services with total Medicare billing of $430,308. Data is available for 4 years (2020–2023), covering 58 distinct procedure/service records.
Ad
Practice Information
- Specialty Anesthesiology
- Other Specialties Interventional Pain Medicine, Pain Medicine
- Location New York, NY
- Active Since 10/04/2005
- Last Updated 08/12/2022
- Taxonomy Code 207L00000X
- Entity Type Individual
- NPI Number 1073500013
Products in Payments
- ZOHYDRO ER (Drug) $92,315
- Morphabond ER (Drug) $57,085
- Movantik (Drug) $51,693
- ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH (Drug) $42,248
- Nucynta (Drug) $33,438
- MOVANTIK (Drug) $18,341
- Xtampza (Drug) $17,925
- CL-108 (Drug) $12,861
- Xtampza ER (Drug) $8,174
- Evzio (Drug) $6,497
- VANTRELA (Drug) $4,091
- LUCEMYRA (Drug) $3,738
- VIVLODEX (Drug) $3,540
- HTX-011 (Drug) $3,502
- Qutenza (Drug) $3,175
- EXPAREL (Drug) $2,513
- Amitiza (Drug) $2,108
- Zynrelef (Drug) $1,500
- ANJESO (Drug) $1,415
- RELISTOR (Drug) $857.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Anesthesiology Doctors in New York
Dr. Marc Dickstein, M.d, M.D
Anesthesiology — Payments: $710,891
Anesthesiology $710,891
Ms. Kiran Patel, Md, Daba, Dapm, MD, DABA, DAPM
Anesthesiology — Payments: $625,726
Anesthesiology $625,726
Dr. Admir Hadzic, M.d, M.D
Anesthesiology — Payments: $618,396
Anesthesiology $618,396
Christopher Riegler, Md, MD
Anesthesiology — Payments: $488,339
Anesthesiology $488,339
Dr. William Urmey, Md, MD
Anesthesiology — Payments: $467,669
Anesthesiology $467,669
Mr. Christopher Dimeo, Md, MD
Anesthesiology — Payments: $434,740
Anesthesiology $434,740